Roche Pharmaceuticals is teaming up with the Ministry of Health (MOH) to launch the China Organ Transplant Development Program, according to Beijing Youth Daily December 16.

Roche Pharmaceuticals is teaming up with the Ministry of Health (MOH) to launch the China Organ Transplant Development Program, according to Beijing Youth Daily December 16.
The first phase of the program will span two years. The program will focus on improving the organ transplant registration system, boosting academic exchanges at home and abroad, expanding transplant recipient education programs, and establishing a system to manage patients with renal failure who are awaiting transplants. Products marketed by Roche in China used in the transplant community include CellCept (mycophenolate mofetil), Valcyte (valganciclovir), and Zenapax (daclizumab). As of 2008, a total of 86,800 organ transplants have been performed in China - an annual figure second only to the US.